



Contents lists available at ScienceDirect

Tetrahedron

journal homepage: [www.elsevier.com/locate/tet](http://www.elsevier.com/locate/tet)

# The modified trifluoromethylation protocol applicable to electronically deficient iodopyridinones

Tomoko Kawasaki-Takasuka\*, Takashi Yamazaki

Division of Applied Chemistry, Institute of Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei 184-8588, Japan

## ARTICLE INFO

### Article history:

Received 2 May 2015

Received in revised form 8 July 2015

Accepted 10 July 2015

Available online xxx

### Keywords:

Trifluoromethylation

Iodopyridinone

Ruppert–Prakash reagent

Trifluoromethyl copper reagents

Hexamethylphosphoric triamide

## ABSTRACT

Utilization of a mixed solvent system of DMF/HMPA=1/1 (v/v) to the KF/CuI/TMSCF<sub>3</sub> reagent system proved to significantly affect the reaction, realizing convenient introduction of a trifluoromethyl (CF<sub>3</sub>) group not only to electron-deficient iodopyridinones with quite a few previous successful examples but also to aliphatic vinylic iodides.

© 2015 Elsevier Ltd. All rights reserved.

## 1. Introduction

The pyridin-2(1H)-one structure is widely found in a variety of biologically active naturally occurring compounds (Fig. 1).

For example, camptothecin,<sup>1</sup> isolated from *Camptotheca acuminata* in 1966, and its derivatives, topotecan and irinotecan, are known to show prominent anticancer activity like the case of




Fig. 1. Bioactive pyridinone derivatives.

lyconadin A.<sup>2</sup> Significant attention to huperzine A<sup>3</sup> from *Huperzia serrata* has been recently paid for its pharmaceutical activity to the Alzheimer's disease. Pirfenidone has been employed against fibrotic disorder and its derivatives with a CF<sub>3</sub> group were disclosed as promising antiasthma compounds.<sup>4</sup> 3-Iodo-4-phenoxy-pyridin-2(1H)-ones were also reported as a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.<sup>5</sup> Thus, it is easily understood that pyridinone compounds are wide-spread in nature and some of them display attractive activities for a variety of diseases.

Until now, although introduction of a CF<sub>3</sub> group to bioactive lead compounds has been performed in diverse manners for modification of original activities,<sup>6</sup> a scarce number of methods have been developed for electron-deficient pyridinones. One route to access 3-(trifluoromethyl)pyridin-2(1H)-one derivatives is substitution of an iodine atom for a CF<sub>3</sub> group by means of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate in the presence of copper(I) iodide.<sup>7</sup> Another known process is direct installation of CF<sub>3</sub> radical to pyridin-2(1H)-ones, which is realized either by CF<sub>3</sub>CO<sub>2</sub>H/XeF<sub>2</sub><sup>8</sup> or CF<sub>3</sub>CO<sub>2</sub>Na/CuI<sup>9</sup> systems, and the more attractive generation of this radical was devised by Yamakawa et al. using a combination of CF<sub>3</sub>I, a Fe(II) catalyst, and H<sub>2</sub>O<sub>2</sub> in DMSO.<sup>10</sup> Recently, the Baran's group attained very practical C–H trifluoromethylation of heterocycles by CF<sub>3</sub>SO<sub>2</sub>Na<sup>11</sup> or (CF<sub>3</sub>SO<sub>2</sub>)<sub>2</sub>Zn<sup>12</sup> with focusing on various heteroaromatics as substrates, however this protocol sometimes suffers from low regioselectivity.

Extension of our interest to pyridines allowed to find out a relatively larger number of precedented work in the literature. For

\* Corresponding author. Tel./fax: +81 42 388 7038; e-mail address: [takasuka@cc.tuat.ac.jp](mailto:takasuka@cc.tuat.ac.jp) (T. Kawasaki-Takasuka).

<http://dx.doi.org/10.1016/j.tet.2015.07.029>

0040-4020/© 2015 Elsevier Ltd. All rights reserved.



Download English Version:

<https://daneshyari.com/en/article/5214755>

Download Persian Version:

<https://daneshyari.com/article/5214755>

[Daneshyari.com](https://daneshyari.com)